Stable Cell Lines for Efflux Transport Protein Silencing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for predicting drug absorption in humans and animals are limited by the inability to accurately account for the contributions of multiple efflux transport proteins, leading to skewed results due to the use of chemical inhibitors that affect other cellular processes and provide only transient gene expression inhibition.

Innovation Solution

The development of stable cell lines and methods using nucleic acid molecules, such as RNA interference, to specifically inhibit the expression of membrane efflux transport proteins like P-glycoprotein, Multidrug Resistance-Associated Protein 2, and Breast Cancer Resistance Protein, allowing for permanent and sequence-specific silencing of these proteins using lentivirus vectors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If chemical inhibitors are used to block efflux transport proteins, then drug absorption prediction is attempted, but the results are skewed due to off-target effects on other cellular processes

Engineering Contradiction:
Improveaccuracy of drug absorption predictionVSAvoidoff-target effects on cellular processes
Core Design Contradiction:
Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and isolates the specific function of efflux transport proteins by using RNA interference to selectively silence only these target proteins, while leaving other cellular processes untouched. This specificity eliminates the off-target effects that plague chemical inhibitor approaches.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention introduces RNA interference molecules as an intermediary mechanism between the researcher and the efflux transport proteins. These RNA molecules specifically bind to and silence target genes without directly interacting with or affecting other cellular proteins, thus mediating the inhibition without off-target effects.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If transient gene expression inhibition is used, then efflux transport protein activity is reduced, but the inhibition is not permanent requiring repeated treatments

Engineering Contradiction:
Improveconsistency of inhibitionVSAvoidduration of gene expression inhibition
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

The invention performs preliminary action by stably integrating the RNA interference machinery into the cell genome beforehand. This stable integration ensures that the inhibition of efflux transport proteins is maintained permanently or long-term, eliminating the need for repeated treatments and providing consistent results throughout the experiment.

Inventive Principle:
Principle #10Preliminary action

3Adaptability or versatility

If multiple efflux transport proteins are studied simultaneously, then comprehensive absorption prediction is possible, but the complexity of controlling and differentiating their individual contributions increases

Engineering Contradiction:
Improveability to study multiple transport proteinsVSAvoidcomplexity of controlling protein expression
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The invention segments the study of multiple efflux transport proteins by creating separate stable cell lines, each with specific RNA interference targeting one particular transport protein. This segmentation allows researchers to study each protein's individual contribution to drug absorption while maintaining the ability to compare results across multiple segmented cell line models.

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables accurate prediction of gastrointestinal absorption by stably controlling the expression of efflux transport proteins, providing reliable and long-term inhibition, which improves the accuracy of drug absorption studies and identifies the relative contributions of each transport protein.

Implementation Method 1

The development of stable cell lines and methods using nucleic acid molecules, such as RNA interference, to specifically inhibit the expression of membrane efflux transport proteins

Methodology Applied
Scientific EffectRNA interference:

Data Source

PatentUS8110398B2Stable cell lines and methods for evaluating gastrointestinal absorption of chemicals
Publication Date: 2012.02.07 PHARMARON (EXTON) LAB SERVICES LLC
  • US8110398B2 patent drawing
  • US8110398B2 patent drawing
  • US8110398B2 patent drawing

AI summary

Nucleic acids and vectors for interfering with the expression of membrane efflux transport proteins in cells that express such proteins are provided. Also provided are cells and cell lines comprising such nucleic acids and vectors. Methods for screening chemicals and biomolecules for gastrointestinal absorption in animals, and kits for practicing such methods are also provided.